Navigation Links
Alkylating in Medical Technology

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... conjugate was well-tolerated in cynomolgous monkeys and mouse models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) The effectiveness of a cleavable linker over a non-cleavable linker when used with ...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare ...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

... Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare ...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma

... and apoptosis. In preclinical in vitro and animal model studies it shows activity against human tumors including melanoma and is synergistic with alkylating agents including dacarbazine. Fifty (50) patients were treated with Amplimexon at MTD (maximum tolerated dose) during the Phase II portion of the ...

Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Sexual Function Affected by Stem Cell Transplant According to Long-Term Study

... sexual dysfunction in transplant patients is likely caused by systemic therapies, such as total body irradiation and chemotherapy drugs known as alkylating agents, which are known to permanently damage endocrine glands that play a critical role in the development and regulation of the reproductive ....

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

... the highly active and noveltherapies of VELCADE and lenalidomide / dexamethasone and also explore the incremental benefit of cyclophosphamide, an alkylating agent, which in previous studies has shown synergistic activity with VELCADE. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) "The ...

Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer

... important part of the overall clinical development program for this novel alkylating agent." Ms. Cahill added, "We are encouraged by this promising data in ... two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in ...

Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual Meeting of the American Association of Cancer Research (AACR)

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal ...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

... Inc., as Campath(R). The product is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Determination of the effectiveness of Campath is based on overall response rates. Comparative, ...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

... in the PPE population. Use with Systemic Immunosuppressive Medications Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines (see ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

... in the PPE population. Use with Systemic Immunosuppressive Medications Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines (see ...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

... by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute ...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

... role of VELCADE." Weekly VELCADE, Cyclophosphamide and Prednisone in Myeloma (Abstract #PO- 639) "VELCADE has shown synergistic activity with alkylating agents by generating substantially high and durable complete remission rates," said Donna Reece, M.D., Princess Margaret Hospital. "This is an ...
Other Contents
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into the NAPW VIP Professional Woman ... prestigious distinction for leadership in academics. With more than ... is the nation’s leading networking organization exclusively for professional ... important distinction,” said NAPW President Star Jones. “She is ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in business. NAPW is the nation’s ... than 700,000 members and over 200 operating Local Chapters. ... honor,” said NAPW President Star Jones. “Her perseverance, work ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Selma Tansey as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in mental health. ... professional women, boasting more than 700,000 members and over ... Selma with this important honor," said NAPW President Star ...
(Date:6/1/2015)... Dr. Robert G. Schwartz , ... & Rehabilitation, P.A., has published a new article ... therapy for knees, and highlights it as a ... arthroscopy or knee joint replacement. , Dr. Schwartz, ... and Regenerative Medicine, writes that both autologus and ...
(Date:6/1/2015)... June 01, 2015 Ticket Down announces that ... NBA Western Conference Finals and now will face the Cleveland ... be held at the Oracle Arena in Oakland and the ... 2014-15 National Basketball Association season, the Golden State Warriors were ... a team that learned from their playoff failures from the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3
Other TagsOther Tags